Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bristol-Myers Squibb, Imclone Expand Erbitux Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Bristol-Myers Squibb, Imclone Expand Erbitux Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ImClone Systems and Bristol-Myers Squibb have amended the terms of their Erbitux agreement regarding the development and promotion in North America. Under this amendment, the companies have expanded the investment in the ongoing clinical development program for Erbitux by as much as several hundred million dollars. BMS will be responsible for development costs up to a threshold value. The companies will share costs beyond this threshold.

The companies added Phase II and Phase III trials to further explore the activity of Erbitux in a variety of therapeutic settings. The results of these studies will be used to support new registrational opportunities for the drug. The clinical program will supplement the existing data for Erbitux in colorectal and head and neck cancers and explore the use of Erbitux in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate.

“By broadening the Erbitux development program with ImClone Systems and utilizing pharmacogenomic markers and other screening technologies, we intend to enhance cancer patient outcomes which may further differentiate Erbitux from other commercially available antibodies,” said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, R&D, BMS. “This plan further demonstrates BMS’s focus on the development of innovative compounds, like Erbitux, and highlights our company’s dedication to partnerships that can maximize the potential of products in our portfolio.”

“This new commitment to Erbitux represents one of the largest and broadest cancer-focused development programs for any antibody. The agreement aligns the development and commercialization of Erbitux at ImClone Systems and BMS to benefit both companies’ shareholders, and most importantly, cancer patients,” stated Alexander J. Denner, Ph.D., chairman, executive committee of ImClone Systems. “We are very pleased by this agreement and look forward to the two companies working in harmony.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters